東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Safety and Effectiveness: The FDA's ...

Philip Gentry, Elissa.

FindBook

Google Book

Amazon

博客來

Safety and Effectiveness: The FDA's Approach to Risk in Prescription Medication.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Safety and Effectiveness: The FDA's Approach to Risk in Prescription Medication./
作者:	Philip Gentry, Elissa.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2016,
面頁冊數:	177 p.
附註:	Source: Dissertation Abstracts International, Volume: 77-12(E), Section: A.
Contained By:	Dissertation Abstracts International77-12A(E).
標題:	Economics. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10151710
ISBN:	9781369064148

Safety and Effectiveness: The FDA's Approach to Risk in Prescription Medication.
Philip Gentry, Elissa.

Safety and Effectiveness: The FDA's Approach to Risk in Prescription Medication. - Ann Arbor : ProQuest Dissertations & Theses, 2016 - 177 p.

Source: Dissertation Abstracts International, Volume: 77-12(E), Section: A.

Thesis (Ph.D.)--Vanderbilt University, 2016.

The FDA ensures that prescription drugs in America are generally "safe and effective" for the uses for which they are prescribed. Given the inherent tradeoff between rigorously vetting drugs and delaying alternative treatments for patients, however, there are areas in which prescription risks are left unregulated or are unable to be precisely quantified. In these areas where drug risks can be heterogeneous, physicians' ability to assess, and the market's ability to price, risk is particularly important. This dissertation focuses on the legal framework surrounding consumer drug choice.

ISBN: 9781369064148Subjects--Topical Terms:

517137
Economics.

Safety and Effectiveness: The FDA's Approach to Risk in Prescription Medication.
LDR:04627nmm a2200349 4500 001 2128453
005 20180104132946.5
008 180830s2016 ||||||||||||||||| ||eng d
020 $a 9781369064148
035 $a (MiAaPQ)AAI10151710
035 $a AAI10151710
040 $a MiAaPQ $c MiAaPQ
100 1 $a Philip Gentry, Elissa. $3 3290629
245 1 0 $a Safety and Effectiveness: The FDA's Approach to Risk in Prescription Medication.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2016
300 $a 177 p.
500 $a Source: Dissertation Abstracts International, Volume: 77-12(E), Section: A.
500 $a Adviser: W. Kip Viscusi.
502 $a Thesis (Ph.D.)--Vanderbilt University, 2016.
520 $a The FDA ensures that prescription drugs in America are generally "safe and effective" for the uses for which they are prescribed. Given the inherent tradeoff between rigorously vetting drugs and delaying alternative treatments for patients, however, there are areas in which prescription risks are left unregulated or are unable to be precisely quantified. In these areas where drug risks can be heterogeneous, physicians' ability to assess, and the market's ability to price, risk is particularly important. This dissertation focuses on the legal framework surrounding consumer drug choice.
520 $a Chapter 1 begins by measuring consumers' preferences with respect to ambiguity in the risk that a drug is safe or ineffective in the presence of framing effects. It uses an incentivized experiment on Vanderbilt undergraduates to understand consumers' preferences if they were given explicit information about drug risks. These deviations from ambiguity neutrality depend on context: the Chapter finds that framing effects result in ambiguity-seeking behavior in the "loss domain" and ambiguity-averse behavior in the "gains domain." The results suggest that alleviating some ambiguity through uniform recommendations or physician intermediaries might actually lead to patients choosing better treatment options.
520 $a Chapter 2 empirically examines the consumption of narrow therapeutic index (NTI) drugs, an area in which there was a perceived but unregulated risk. The Chapter tests whether third-party payers contributions are consistent with patients' preferences against risky drugs, particularly drugs in which switching is costly. The results support this idea, as there is evidence of a price penalty for NTI status in all first- and third-party payers' contributions. The gap between brand-name and generic drugs is also smaller for NTI drugs than for non-NTI drugs, consistent with costly switching. Finally, the Chapter examines consumption behavior and finds evidence of version loyalty, consistent with costly switching. The Chapter concludes that third-party payers might be adequate agents of patients in taking risk preferences into account in their pricing decisions even absent direct government regulation.
520 $a Chapter 3 measures the effect of a False Claims Act settlement on relinquishment of inappropriate off-label uses. It finds a significant average drop in off-label prescriptions after an FCA suit is settled. It further utilizes a case study of neurontin to disentangle the response of different payers to both scientific and legal information shocks. It finds heterogeneity in relative relinquishment by payer and finds evidence consistent with the relinquishment being spurred by the litigation process.
520 $a This dissertation seeks to understand the relationship between risk preferences and regulation in the context of pharmaceutical drugs. Chapter 1 discusses the underlying issue of ambiguity in pharmaceutical drug risks. Chapters 2 and 3 examine two contexts in which drug risks were uncertain or not well-quantified and discuss whether explicit regulation is necessary. Chapter 2 finds that the market seems sensitive to risk even in the absence of government regulation. Chapter 3 finds that the False Claims Act can provide industry signals as to the appropriateness of off-label uses but cautions that this function may be undermined by further expansion of the FCA. The results provide an insight into how the legal framework surrounding pharmaceutical regulation interacts with consumer risk preferences and where explicit regulation is necessary and where the market might be well-equipped to compensate risk.
590 $a School code: 0242.
650 4 $a Economics. $3 517137
650 4 $a Law. $3 600858
650 4 $a Pharmaceutical sciences. $3 3173021
690 $a 0501
690 $a 0398
690 $a 0572
710 2 $a Vanderbilt University. $3 1017501
773 0 $t Dissertation Abstracts International $g 77-12A(E).
790 $a 0242
791 $a Ph.D.
792 $a 2016
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10151710